How to appeal a Premera Blue Cross kidney disease — ckd, esrd, igan, adpkd denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for kidney disease — ckd, esrd, igan, adpkd

Cited policy: BCBS / Anthem Medical Policy — Rituximab for Membranous Nephropathy (off-label)

PLA2R-positive membranous + persistent proteinuria + KDIGO 2021 GN classification.

How Premera Blue Cross denies kidney disease — ckd, esrd, igan, adpkd — and how to counter it

Where Premera Blue Cross pushes back: 1) 'Off-label'; 2) Calcineurin inhibitor not tried first; 3) Insufficient anti-PLA2R titer.

Counter-arguments that hold up: MENTOR NEJM 2019 — non-inferior + superior at 24 months vs cyclosporine for MN remission. KDIGO 2021 GN guideline lists rituximab as first-line for moderate-risk MN. PLA2R antibody titer monitoring per Hofstra criteria.

What Premera Blue Cross typically denies for kidney disease — ckd, esrd, igan, adpkd

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For kidney disease — ckd, esrd, igan, adpkd, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the kidney disease — ckd, esrd, igan, adpkd treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Tarpeyo (IgAN)
• Filspari
• Farxiga (CKD)
• Jardiance (CKD)
• Kerendia
• Jynarque (ADPKD)

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.